XNCR stock forecast, quote, news & analysis
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases... Show more
Why Xencor (XNCR) Stock Is Up +50.2% in the Last 30 Days
Key Takeaways
- XNCR advanced approximately 50.2% in the 30-day period, rising from a $14.98 close on July 15, 2026, to roughly $22.50 in mid-August.
- The move accelerated after Xencor announced that Phase 1 expansion-cohort data for XmAb819 in advanced clear cell renal cell carcinoma was selected for an oral presentation at ESMO 2026.
- A $105 million agreement with Alexion resolved the U.S. Ultomiris royalty dispute, preserved ex-U.S. royalties, and extended Xencor's operating runway through 2028.
- Second-quarter 2026 results showed $51.2 million in revenue and a narrower net loss than the prior-year period, reinforcing the upward trend.
- Over the last quarter, XNCR climbed about 89.4% from an $11.88 close on May 14, 2026.
Xencor (XNCR) Company Overview and Market Position
Xencor, Inc. is a clinical-stage biopharmaceutical company that designs engineered antibodies for cancer and autoimmune diseases. Its proprietary XmAb technology platform is used to modify antibody structure and create new therapeutic mechanisms, including bispecific T-cell engagers and extended half-life antibodies. More than 20 XmAb-engineered candidates are in clinical development, and multiple partnered medicines are marketed. Key wholly owned programs include XmAb819 (ENPP3 x CD3) for advanced clear cell renal cell carcinoma, XmAb942 for ulcerative colitis, XmAb541 for gynecologic and germ cell tumors, and XmAb657 for idiopathic inflammatory myopathies. The company also generates collaboration, milestone, and royalty revenue from partners such as Alexion, part of AstraZeneca (AZN), and Incyte (INCY). Investors follow XNCR for pipeline readouts and royalty-linked cash flow.
Xencor (XNCR) Stock Price Performance: Last 30 Days vs. Quarter
Using closing prices from available market data, XNCR closed at $14.98 on July 15, 2026, and traded near $22.50 by mid-August. That represents a 30-day gain of about 50.2%. The stock reached a 52-week high of $23.34 on August 12 before easing slightly.
The quarterly trend is stronger. XNCR closed at $11.88 on May 14, 2026, so the rise to roughly $22.50 translates to an advance of approximately 89.4% over the three-month window. The shares bottomed near $10.41 on May 19 and then rebuilt through June before the sharp July acceleration.
What Drove XNCR Stock Price in the Last 30 Days
The first major catalyst arrived July 17, when Xencor announced that Phase 1 expansion-cohort results for XmAb819 in advanced clear cell renal cell carcinoma had been accepted for a proffered paper oral presentation at the ESMO Congress 2026. The update supported dose selection for a planned pivotal study and was followed by a single-session gain of roughly 17%.
Momentum continued into the following sessions, with XNCR reaching 52-week highs on July 20 and July 21 as investors reassessed the company's wholly owned oncology and autoimmune pipeline. Attention also centered on XmAb942, which is advancing in the Phase 2b XENITH-UC trial in ulcerative colitis with interim results expected near year-end 2026.
A second catalyst came on July 29, when Xencor agreed to receive $105 million from Alexion in two equal payments to settle the U.S. Ultomiris royalty dispute. The agreement preserved royalties on ex-U.S. sales, and management said the operating runway now extends through 2028. XNCR closed at $21.49 on July 30.
On August 5, second-quarter results added fundamental support. Revenue was $51.2 million, up from $43.6 million a year earlier, while net loss narrowed to $0.29 per share from $0.41. Xencor recognized $27.6 million in royalty revenue tied to the dispute period and guided to $420 million to $440 million in cash and marketable securities at year-end 2026.
What Drove XNCR Stock Performance Over the Last Quarter
The broader three-month advance reflects a shift in how the market is valuing Xencor's pipeline and balance sheet. After the stock fell to roughly $10.41 in mid-May, shares recovered as investors looked ahead to a data-rich second half of 2026 across oncology and autoimmune programs. The ESMO presentation acceptance for XmAb819, progress on XmAb942 in ulcerative colitis, and updates planned for XmAb541, plamotamab, and XmAb657 gave the rally a catalyst-rich foundation. The Alexion resolution then removed a meaningful royalty uncertainty while adding near-term cash, and the second-quarter report showed improving financial flexibility. Together, these developments transformed a gradual recovery into a sharp re-rating.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated group of AI trading bots drawn from a platform that offers hundreds of bots trading thousands of tickers. Only the top-performing and most relevant strategies are featured in this section, making it a focused starting point for traders monitoring automated approaches. Bots vary by strategy, timeframe, and performance metrics, so users can compare different models and decide which signals fit their own research process. Traders interested in systematic market analysis can explore the section to see which automated strategies are currently attracting attention.
XNCR Stock Forecast Drivers: What Investors Should Watch Next
The next major catalyst is the ESMO Congress 2026, scheduled for October 23–27, where XmAb819 expansion-cohort data will be presented; the abstract is expected to be available October 18. Investors will also watch the Phase 2b XENITH-UC trial of XmAb942 in ulcerative colitis, with an interim update expected near year-end 2026, and second-half 2026 updates for XmAb541, plamotamab, and XmAb657. The planned first-in-human study of XmAb412 and the initial $52.5 million Alexion payment in August 2026 are additional near-term items. Broader factors include biotech sector sentiment, interest-rate expectations, clinical trial execution, and competitive developments in T-cell engagers and TL1A antibodies. These factors can affect volatility in either direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
XNCR sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for XNCR moved above the 200-day moving average on July 22, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on XNCR as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on August 11, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in of 254 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 186 cases where XNCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XNCR broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.759) is normal, around the industry mean (20.109). P/E Ratio (0.000) is within average values for comparable stocks, (24.032). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (18.182) is also within normal values, averaging (445.198).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology